Hansa Biopharma announced the closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA Hansa Biopharma AB and SERB S.A. announced that the required regulatory approvals have been obtained and that the previously announced €115 million exclusive licensing transaction with SERB has closed. The company also announced that Maria Törnsén, […]
Seven internationally recognized nephrology experts join R1’s Scientific Advisory Board Strengthens scientific and clinical guidance as AP306 advances into global Phase 2b development for the treatment of hyperphosphatemia in chronic kidney disease Board chaired by Glenn M. Chertow, M.D., MPH, Professor of Medicine, Epidemiology and Population Health, and Health Policy at Stanford University School of […]
Hansa Biopharma appointed Adam Cutler as new Chief Financial Officer Hansa Biopharma AB announced the appointment of Adam Cutler as its new Chief Financial Officer (CFO) and member of the Executive Committee, effective June 22, 2026. Adam succeeds Evan Ballantyne, who has served as CFO since 2024. Evan will continue in the role until June […]
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease R1 Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the […]
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate Advancing Phase 2b […]
